COEP Stock Overview
Operates as a biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Coeptis Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$1.28 |
| 52 Week Low | US$0.15 |
| Beta | -0.94 |
| 11 Month Change | -6.22% |
| 3 Month Change | -6.26% |
| 1 Year Change | -83.22% |
| 33 Year Change | -98.05% |
| 5 Year Change | n/a |
| Change since IPO | -98.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| COEP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | 2.4% | 2.2% |
| 1Y | -83.2% | 16.2% | 31.7% |
Return vs Industry: COEP underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: COEP underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| COEP volatility | |
|---|---|
| COEP Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: COEP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COEP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Dave Mehalick | coeptistx.com |
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology.
Coeptis Therapeutics Holdings, Inc. Fundamentals Summary
| COEP fundamental statistics | |
|---|---|
| Market cap | US$8.00m |
| Earnings (TTM) | -US$11.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs COEP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COEP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.62m |
| Earnings | -US$11.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 34.2% |
How did COEP perform over the long term?
See historical performance and comparison